COVID-19 Vaccination in Patients with Inborn Errors of Immunity Reduces Hospitalization and Critical Care Needs Related to COVID-19: a USIDNET Report.

BACKGROUND: The CDC and ACIP recommend COVID-19 vaccination for patients with inborn errors of immunity (IEI). Not much is known about vaccine safety in IEI, and whether vaccination attenuates infection severity in IEI. OBJECTIVE: To estimate COVID-19 vaccination safety and examine effect on outcomes in patients with IEI. METHODS: We built a secure registry database in conjunction with the US Immunodeficiency Network to examine vaccination frequency and indicators of safety and effectiveness in IEI patients. The registry opened on January 1, 2022, and closed on August 19, 2022. RESULTS: Physicians entered data on 1245 patients from 24 countries. The most common diagnoses were antibody deficiencies (63.7%). At least one COVID-19 vaccine was administered to 806 patients (64.7%), and 216 patients received vaccination prior to the development of COVID-19. The most common vaccines administered were mRNA-based (84.0%). Seventeen patients were reported to seek outpatient clinic or emergency room care for a vaccine-related complication, and one patient was hospitalized for symptomatic anemia. Eight hundred twenty-three patients (66.1%) experienced COVID-19 infection. Of these, 156 patients required hospitalization (19.0%), 47 required ICU care (5.7%), and 28 died (3.4%). Rates of hospitalization (9.3% versus 24.4%, p < 0.001), ICU admission (2.8% versus 7.6%, p = 0.013), and death (2.3% versus 4.3%, p = 0.202) in patients who had COVID-19 were lower in patients who received vaccination prior to infection. In adjusted logistic regression analysis, not having at least one COVID-19 vaccine significantly increased the odds of hospitalization and ICU admission. CONCLUSION: Vaccination for COVID-19 in the IEI population appears safe and attenuates COVID-19 severity.

New data supporting that early diagnosis and treatment are possible and necessary in intracellular cobalamin depletion: the case of transcobalamin II deficiency.

OBJECTIVES: Transcobalamin II (TC) promotes the cellular uptake of cobalamin (Cbl) through receptor-mediated endocytosis of the TC-cbl complex in peripheral tissues. TC deficiency is a rare disorder that causes intracellular Cbl depletion. It presents in early infancy with a failure to thrive, diarrhea, anemia, agammaglobulinemia, and pancytopenia. Data from five TC-deficient patients including clinical, biochemical, and molecular findings, as well as long-term outcomes, were collected. CASE PRESENTATION: Mutation analysis revealed one unreported pathogenic variant in the TCN2 gene. One patient had exocrine pancreatic insufficiency. We conducted a retrospective analysis of C3 and C3/C2 from dried blood samples, as this is implemented for newborn screening (NBS). We detected a marked increase in the C3/C2 ratio in two samples. Treatment was based on parenteral Cbl. Three patients treated before six months of age had an initial favorable outcome, whereas the two treated later or inadequately had neurological impairment. CONCLUSIONS: This is the first report of Argentinean patients with TC deficiency that detected a new variant in TCN2. NBS may be a tool for the early detection of TC deficiency. This data emphasizes that TC deficiency is a severe disorder that requires early detection and long-term, aggressive therapy. Accurate diagnosis is imperative, because early detection and treatment can be life-saving.

Expanding spectrum, intrafamilial diversity, and therapeutic challenges from 15 patients with heterozygous CARD11-associated diseases: A single center experience.

CARD11-associated diseases are monogenic inborn errors of immunity involving immunodeficiency, predisposition to malignancy and immune dysregulation such as lymphoproliferation, inflammation, atopic and autoimmune manifestations. Defects in CARD11 can present as mutations that confer a complete or a partial loss of function (LOF) or contrarily, a gain of function (GOF) of the affected gene product. We report clinical characteristics, immunophenotypes and genotypes of 15 patients from our center presenting with CARD11-associated diseases. Index cases are pediatric patients followed in our immunology division who had access to next generation sequencing studies. Variant significance was defined by functional analysis in cultured cells transfected with a wild type and/or with mutated hCARD11 constructs. Cytoplasmic aggregation of CARD11 products was evaluated by immunofluorescence. Nine index patients with 9 unique heterozygous CARD11 variants were identified. At the time of the identification, 7 variants previously unreported required functional validation. Altogether, four variants showed a GOF effect as well a spontaneous aggregation in the cytoplasm, leading to B cell expansion with NF-κB and T cell anergy (BENTA) diagnosis. Additional four variants showing a LOF activity were considered as causative of CARD11-associated atopy with dominant interference of NF-kB signaling (CADINS). The remaining variant exhibited a neutral functional assay excluding its carrier from further analysis. Family segregation studies expanded to 15 individuals the number of patients presenting CARD11-associated disease. A thorough clinical, immunophenotypical, and therapeutic management evaluation was performed on these patients (5 BENTA and 10 CADINS). A remarkable variability of disease expression was clearly noted among BENTA as well as in CADINS patients, even within multiplex families. Identification of novel CARD11 variants required functional studies to validate their pathogenic activity. In our cohort BENTA phenotype exhibited a more severe and expanded clinical spectrum than previously reported, e.g., severe hematological and extra hematological autoimmunity and 3 fatal outcomes. The growing number of patients with dysmorphic facial features strengthen the inclusion of extra-immune characteristics as part of the CADINS spectrum. CARD11-associated diseases represent a challenging group of disorders from the diagnostic and therapeutic standpoint, especially BENTA cases that can undergo a more severe progression than previously described.

Inflammatory cutaneous lesions and pulmonary manifestations in a new patient with autosomal recessive ISG15 deficiency case report.

Interferon-stimulated gene 15 (ISG15) was the first ubiquitin-like modifier protein identified that acts by protein conjugation (ISGylation) and is thought to modulate IFN-induced inflammation. Here, we report a new patient from a non-consanguineous Argentinian family, who was followed for recurrent ulcerative skin lesions, cerebral calcifications and lung disease. Whole Exome Sequencing (WES) revealed two novel compound heterozygous variants (c.285del and c.299_312del, NM_005101.4 GRCh37(hg19), both classified as pathogenic according to ACMG criteria) in the ISG15 gene, resulting in a complete deficiency due to disruption of the second ubiquitin domain of the corresponding protein. The clinical phenotype of this patient is unique given the presence of recurrent pulmonary manifestations and the absence of mycobacterial infections, thus resulting in a phenotype distinct from that previously described in patients with biallelic loss-of-function (LOF) ISG15 variants. This case highlights the role of ISG15 as an immunomodulating factor whose LOF variants result in heterogeneous clinical presentations.

Eficacia del tratamiento ortopédico en pie plano flexible pediátrico: revisión sistemática / Eficacy of orthopediac treatment of flexible flatfoot in pediatrics: A systematic review

Introducción: El pie plano flexible es una de las entidades ortopédicas más frecuentes en Pediatría. Algunos autores lo consideran una variante anatómica. La incertidumbre en cuanto a su evolución y pronóstico, sumado a la preocupación y demanda por parte de los padres, hace que en muchas ocasiones se indique tratamiento ortésico. Metodología: se realizó una búsqueda sistemática en Medline, Lilacs, Cochrane y Google académico, usando los términos therapy, flatfoot, flatfeet, pie plano y pes planus; población hasta los 18 años, publicaciones hasta abril 2017 y restringiendo por idiomas español e inglés. Para el aná- lisis de los artículos se utilizaron la guía de lectura crítica del Hospital Garrahan y la escala de calidad metodológica JADAD. Resultados: de 778 artículos encontrados, 421 correspondían a pacientes con enfermedad de base, 194 evaluaban corrección quirúrgica, 144 eran descriptivos, 7 comparaban diferentes ortesis entre sí y 7 eran revisiones de trabajos. Finalmente fueron analizados 5 trabajos (cuatro ECCAs y un estudio de cohorte). De los 5 artículos, 2 poseían aceptable y muy buena calidad metodológica según la escala JADAD, ninguno demostrando diferencias significativas con el tratamiento ortésico. De los 3 restantes, sólo uno halló mejores resultados en cuanto al alivio del dolor y de la marcha combinando ortesis con ejercicios (RR 0.33 y 0.29 respectivamente). Conclusión: en base a esta revisión no hay evidencia científica que demuestre la eficacia del uso de ortesis para la corrección del pie plano flexible en la población pediátrica sana.(AU)

Introduction: Flexible flatfoot is one of the most common orthopedic findings in children. Some authors consider the entity to be a normal anatomical variant. Uncertainty regarding outcome and prognosis added to the worries and demands of the parents often results in the indication of orthotic treatment. Methods: A systematic search was conducted in Medline, Lilacs, Cochrane, and Google academics using the terms therapy, flatfoot, flatfeet, and pes planus; population up to 18 years of age, publications until April 2017, in Spanish and English. For the analysis of the articles the critical reading guidelines of Hospital Garrahan and the JADAD scale for methodological quality were used. Results: Of 778 articles found, 421 were related to patients with an underlying disease, 194 evaluated surgical correction, 144 were descriptive studies, 7 compared different orthosis, and 7 were review studies. Finally, 5 studies were analyzed (four randomized controlled trials (RCT) and one cohort study). Of the five studies, two were considered acceptable and of good quality on the JADAD scale. None of the studies showed significant differences with orthotic treatment. Of the three remaining studies, only one found better results regarding pain relief and gait improvement with orthosis combined with exercise (RR 0.33 and 0.29, respectively). Conclusion: Based on this review, there is no scientific evidence that shows efficacy of the use of orthosis for the correction of flatfoot in healthy children. (AU)